News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • U.S. forces launched military strikes against Iran this morning.
  • The U.S. dollar held near this week's highs versus major currencies.
  • Safe-haven flows increased demand for the dollar after the strikes.
  • Brent and WTI crude prices rose on renewed Middle East supply concerns.
  • Market participants flagged increased geopolitical risk to energy supply stability.
  • Heightened tensions drove risk-off positioning and short-term market uncertainty.

Latest Articles

Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease

Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease

Prime Medicine announced that New Zealand's regulatory authority approved its clinical trial application for PM577a, the company's investigational Prime Editor therapy for Wilson Disease targeting the H1069Q ATP7B gene mutation. This clearance marks the first clinical authorization for Prime Medicine's in vivo Prime Editing treatment, enabling a gl…

Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators

Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators

Clearmind Medicine Inc., a clinical-stage biotech company specializing in non-hallucinogenic neuroplastogen-derived therapeutics, announced that it has been granted a U.S. patent for its molecule MEAI related to regulating binge behaviors such as excessive drinking, eating, and gambling. This patent strengthens the company's intellectual property p…

UBS Rebalances Portfolio Toward Industrial Metals, Scales Back Energy Exposure

UBS Rebalances Portfolio Toward Industrial Metals, Scales Back Energy Exposure

UBS increased its weighting in industrial metals from moderately overweight to overweight, while trimming its energy allocation from overweight to moderately overweight. The bank points to a price pullback in base metals as an entry point amid structural demand and supply constraints, but warns of ongoing near-term volatility. Precious metals remai…

U.S. Futures Edge Up as Middle East Interim Deal Eases Fed-Rate Worries; Movers Include FreeCast, Accenture, Novocure

U.S. Futures Edge Up as Middle East Interim Deal Eases Fed-Rate Worries; Movers Include FreeCast, Accenture, Novocure

U.S. equity futures rose on Thursday as markets reacted to news of an interim Middle East peace agreement that appeared to reduce some of the market's anxieties tied to the Federal Reserve's hawkish posture. At 0750 ET (11:50 GMT) futures contracts showed modest gains, with technology names among the strongest premarket performers. Several individu…

Energy Fuels Pops After $725M Conditional Loan for U.S. Rare Earth Plant

Energy Fuels Pops After $725M Conditional Loan for U.S. Rare Earth Plant

Energy Fuels shares jumped after the U.S. Department of War’s Office of Strategic Capital announced a $725 million conditional loan commitment to support construction of a domestic rare earth separation and metallization facility, a move intended to extend the company's operations beyond uranium processing and address U.S. supply chain gaps for cri…

Spero Therapeutics Stock Jumps After FDA Clears First Oral Carbapenem Utebzi

Spero Therapeutics Stock Jumps After FDA Clears First Oral Carbapenem Utebzi

Spero Therapeutics saw its shares rise 16% following U.S. Food and Drug Administration approval of Utebzi, an oral carbapenem antibiotic developed by GlaxoSmithKline in partnership with Spero. The drug is indicated for adult patients with complicated urinary tract infections, including pyelonephritis, who have limited or no alternative oral treatme…

Norwood Financial Corp Announces Cash Dividend

Norwood Financial Corp Announces Cash Dividend

Norwood Financial Corp announced that its Board of Directors has declared a quarterly cash dividend of $0.32 per share, payable on August 3, 2026, to shareholders of record as of July 15, 2026. This dividend amount remains unchanged from the previous quarter. Norwood Financial operates through its subsidiary Wayne Bank, which serves multiple counti…

Novocure Shares Slide After TRIDENT Phase 3 Misses Primary Endpoint

Novocure Shares Slide After TRIDENT Phase 3 Misses Primary Endpoint

Novocure shares fell sharply in pre-market trading after the company disclosed that its Phase 3 TRIDENT trial did not achieve a statistically significant improvement in overall survival for newly diagnosed glioblastoma patients. The closely watched study showed nearly identical median survival between the trial arms, a development that removes a po…

Cognizant Shares Slide After Accenture Guidance Cut and Berenberg Downgrade

Cognizant Shares Slide After Accenture Guidance Cut and Berenberg Downgrade

Cognizant shares fell sharply in New York premarket trade following an industry-wide reassessment after Accenture trimmed its outlook. A consequential downgrade from Berenberg - moving its rating on Cognizant from Buy to Hold and cutting the price target from $81 to $59 - heightened pressure on the stock as investors weighed the implications of a f…

NorthStrive Biosciences Files Two New U.S. Patent Applications Targeting Muscle Preservation in GLP-1 and Next-Generation Obesity Treatment Markets

NorthStrive Biosciences Files Two New U.S. Patent Applications Targeting Muscle Preservation in GLP-1 and Next-Generation Obesity Treatment Markets

PMGC Holdings Inc., through its subsidiary NorthStrive Biosciences, has filed two new U.S. patent applications expanding their EL-22 and EL-32 intellectual property for potential pharmaceutical use in preserving lean muscle mass during GLP-1 and obesity-related weight loss. These applications represent a strategic shift from animal to human health …